Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
In November a long list of biotech investors and chief executives wrote a letter of concern about “decisional volatility” and turmoil at the F.D.A.
- Simplified Text
-
Biotech investors and chief executives wrote a letter of concern about decisional volatility and turmoil at the FDA
- Confidence Score
- 0.900
- Claim Maker
- The author
- Context Type
- News Article
- Context Details
-
{ "group": "biotech investors and chief executives", "concern": "decisional volatility and turmoil at the FDA" } - UUID
- a1164c05-b55a-4372-a9fc-93306d020747
- Vector Index
- ✗ No vector
- Created
- February 15, 2026 at 4:02 PM (2 months ago)
- Last Updated
- February 15, 2026 at 4:02 PM (2 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
30
claims
🔥
2 months ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.